<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12</volume><submitter>Trejo-Solis C</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Glioblastoma multiforme (GBM) is the most aggressive of the primary brain tumors, with a grim prognosis despite intensive treatment. In the past decades, progress in research has not significantly increased overall survival rate.&lt;h4>Methods&lt;/h4>The in vitro antineoplastic effect and mechanism of action of Casiopeina III-ia (Cas III-ia), a copper compound, on rat malignant glioma C6 cells was investigated.&lt;h4>Results&lt;/h4>Cas III-ia significantly inhibited cell proliferation, inducing autophagy and apoptosis, which correlated with the formation of autophagic vacuoles, overexpression of LC3, Beclin 1, Atg 7, Bax and Bid proteins. A decrease was detected in the mitochondrial membrane potential and in the activity of caspase 3 and 8, together with the generation of intracellular reactive oxygen species (ROS) and increased activity of c-jun NH(2)-terminal kinase (JNK). The presence of 3-methyladenine (as selective autophagy inhibitor) increased the antineoplastic effect of Cas III-ia, while Z-VAD-FMK only showed partial protection from the antineoplastic effect induced by Cas III-ia, and ROS antioxidants (N-acetylcysteine) decreased apoptosis, autophagy and JNK activity. Moreover, the JNK -specific inhibitor SP600125 prevented Cas III-ia-induced cell death.&lt;h4>Conclusions&lt;/h4>Our data suggest that Cas III-ia induces cell death by autophagy and apoptosis, in part due to the activation of ROS -dependent JNK signaling. These findings support further studies of Cas III-ia as candidate for treatment of human malignant glioma.</pubmed_abstract><journal>BMC cancer</journal><pagination>156</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3404907</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Copper compound induces autophagy and apoptosis of glioma cells by reactive oxygen species and JNK activation.</pubmed_title><pmcid>PMC3404907</pmcid><pubmed_authors>Rodriguez-Enriquez S</pubmed_authors><pubmed_authors>Jimenez-Farfan D</pubmed_authors><pubmed_authors>Sotelo J</pubmed_authors><pubmed_authors>Fernandez-Valverde F</pubmed_authors><pubmed_authors>Trejo-Solis C</pubmed_authors><pubmed_authors>Cruz-Salgado A</pubmed_authors><pubmed_authors>Ruiz-Azuara L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Copper compound induces autophagy and apoptosis of glioma cells by reactive oxygen species and JNK activation.</name><description>&lt;h4>Background&lt;/h4>Glioblastoma multiforme (GBM) is the most aggressive of the primary brain tumors, with a grim prognosis despite intensive treatment. In the past decades, progress in research has not significantly increased overall survival rate.&lt;h4>Methods&lt;/h4>The in vitro antineoplastic effect and mechanism of action of Casiopeina III-ia (Cas III-ia), a copper compound, on rat malignant glioma C6 cells was investigated.&lt;h4>Results&lt;/h4>Cas III-ia significantly inhibited cell proliferation, inducing autophagy and apoptosis, which correlated with the formation of autophagic vacuoles, overexpression of LC3, Beclin 1, Atg 7, Bax and Bid proteins. A decrease was detected in the mitochondrial membrane potential and in the activity of caspase 3 and 8, together with the generation of intracellular reactive oxygen species (ROS) and increased activity of c-jun NH(2)-terminal kinase (JNK). The presence of 3-methyladenine (as selective autophagy inhibitor) increased the antineoplastic effect of Cas III-ia, while Z-VAD-FMK only showed partial protection from the antineoplastic effect induced by Cas III-ia, and ROS antioxidants (N-acetylcysteine) decreased apoptosis, autophagy and JNK activity. Moreover, the JNK -specific inhibitor SP600125 prevented Cas III-ia-induced cell death.&lt;h4>Conclusions&lt;/h4>Our data suggest that Cas III-ia induces cell death by autophagy and apoptosis, in part due to the activation of ROS -dependent JNK signaling. These findings support further studies of Cas III-ia as candidate for treatment of human malignant glioma.</description><dates><release>2012-01-01T00:00:00Z</release><publication>2012 Apr</publication><modification>2025-04-21T16:34:13.417Z</modification><creation>2019-03-27T00:55:57Z</creation></dates><accession>S-EPMC3404907</accession><cross_references><pubmed>22540380</pubmed><doi>10.1186/1471-2407-12-156</doi></cross_references></HashMap>